Outlook Therapeutics, Inc. — Director's Dealing 2021

Mar 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Outlook Therapeutics, Inc. (OTLK)
CIK: 0001649989
Period of Report: 2021-03-24

Reporting Person: THURMAN RANDY H (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-24	Stock Option (Right to Buy)	$2.27	A	20873	Acquired	2031-03-24	Common Stock (20873)	Direct

Footnotes

F1: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.